Friday, July 06, 2012 8:43:36 AM
Grupo Iusacell DE Cv (NYSE:CEL)
NETANYA, Israel, July 6, 2012 /PRNewswire/ --
Cellcom Israel Ltd. (NYSE: CEL) (the "Company") announced today that Mr. Shay Livnat, a member of the Company's board of directors, resigned from this office effective July 5, 2012. As a result, Mr. Livnat will not stand for reelection as a director of the Company at the upcoming annual general meeting of shareholders of the Company.
For further details see the Company's most recent annual report on Form 20-F for the year ended December 31, 2011 under "Item 6. Directors, Senior Management and Employees".
About Cellcom Israel
Cellcom Israel Ltd., established in 1994, is the leading Israeli cellular provider; Cellcom Israel provides its approximately 3.362 million subscribers (as at March 31, 2012) with a broad range of value added services including cellular and landline telephony, roaming services for tourists in Israel and for its subscribers abroad and additional services in the areas of music, video, mobile office etc., based on Cellcom Israel's technologically advanced infrastructure. Cellcom Israel operates an HSPA 3.5 Generation network enabling advanced high speed broadband multimedia services, in addition to GSM/GPRS/EDGE networks.Cellcom Israel offers Israel's broadest and largest customer service infrastructure, including telephone customer service centers, retail stores, and service and sale centers, distributed nationwide. Through its broad customer service network Cellcom Israel offers technical support, account information, direct to the door parcel delivery services, internet and fax services, dedicated centers for the hearing impaired, etc. Cellcom Israel further provides through its wholly owned subsidiaries internet connectivity services and international calling services, as well as landline telephone communication services in Israel, in addition to data communication services. Cellcom Israel's shares are traded both on the New York Stock Exchange (CEL) and the Tel Aviv Stock Exchange (CEL). For additional information please visit the Company's website http://www.cellcom.co.il
Company Contact Yaacov Heen Chief Financial Officer investors@cellcom.co.il Tel: +972-52-998-9755 Investor Relations Contact Porat Saar CCG Investor Relations Israel & US cellcom@ccgisrael.com Tel: +1-646-233-2161
SOURCE Cellcom Israel Ltd.
Recent CEL News
- Celadon hails early results of chronic pain trial • Alliance News • 03/08/2024 08:04:45 PM
- Celadon Pharmaceuticals PLC Early Economic Analysis of Feasibility Study Data • RNS Non-Regulatory • 03/07/2024 07:00:13 AM
- Celadon announces start of cannabis supply for two UK companies • Alliance News • 12/14/2023 02:18:53 PM
- Celadon Pharmaceuticals PLC Product Supplied to First Two Sales Contracts • UK Regulatory • 12/14/2023 07:00:00 AM
- Celadon Pharma raises GBP2.0 million via placing • Alliance News • 12/12/2023 05:40:04 PM
- Celadon Pharmaceuticals PLC Fundraise, Update on Future CLN Financing & TVR • UK Regulatory • 12/12/2023 02:00:00 PM
- Celadon shares rise on supply contract worth up to GBP26 million • Alliance News • 11/16/2023 11:45:35 AM
- Celadon Pharmaceuticals PLC New European Sales Contract • UK Regulatory • 11/16/2023 07:00:00 AM
- Celadon Pharmaceuticals raises GBP1.0 million through shares • Alliance News • 10/13/2023 02:42:26 PM
- Celadon Pharmaceuticals PLC Fundraise, CLN Issue, Joint Broker Appointed & TVR • UK Regulatory • 10/13/2023 06:00:00 AM
- Celadon Pharmaceuticals interim loss narrows; optimistic for future • Alliance News • 09/28/2023 11:14:47 AM
- Celadon Pharmaceuticals PLC Interim Results • UK Regulatory • 09/28/2023 06:00:00 AM
- Celadon Pharmaceuticals PLC Notice of Results and Investor Presentation • UK Regulatory • 09/18/2023 06:00:00 AM
- Celadon shares rise on second UK contract win for cannabis product • Alliance News • 09/05/2023 09:48:42 AM
- Celadon Pharmaceuticals PLC New Sales Contract with UK Pharmaceutical Company • UK Regulatory • 09/05/2023 06:00:00 AM
- Celadon receives approval for 5,000 patient clinical cannabis trial • Alliance News • 08/01/2023 10:44:46 AM
- Celadon Pharmaceuticals PLC Approval to roll-out chronic pain clinical trial • UK Regulatory • 08/01/2023 06:00:00 AM
- Celadon Pharmaceuticals PLC Result of AGM • UK Regulatory • 06/29/2023 04:30:00 PM
- Celadon Pharmaceuticals PLC Publication of Annual Report and Notice of AGM • UK Regulatory • 06/05/2023 01:46:00 PM
- Celadon Pharmaceuticals loss widens; confident amid three-year deal • Alliance News • 06/05/2023 11:23:05 AM
- Celadon Pharmaceuticals PLC Final Results for the year ended 31 December 2022 • UK Regulatory • 06/05/2023 06:00:00 AM
- Celadon secures GBP7 million credit facility as product demand grows • Alliance News • 05/30/2023 10:56:00 AM
- Celadon Pharmaceuticals PLC GBP7 Million Committed Credit Facility • UK Regulatory • 05/30/2023 06:00:00 AM
- Celadon Pharmaceuticals PLC Notice of Results and Investor Presentation • UK Regulatory • 05/26/2023 06:00:00 AM
- Celadon Pharmaceuticals PLC West Midlands Mayor Visits Celadon's Facility • RNS Non-Regulatory • 05/25/2023 06:00:00 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM